Table 3 Comparison of PIR.

From: Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI

 

AA%

ADP%

MAADP

Pre-operation

Post-operation

t

p

Pre-operation

Post-operation

t

p

Pre-operation

Post-operation

t

p

Group L (N = 68)

70.14 ± 20.78

79.25 ± 19.14

− 6.515

 < 0.001

59.58 ± 21.46

77.28 ± 18.05

− 9.737

 < 0.001

37.49 ± 11.54

23.52 ± 10.73

12.724

 < 0.001

Group M (N = 218)

76.47 ± 20.09

85.82 ± 16.81*

− 9.766

 < 0.001

61.39 ± 23.06

84.64 ± 15.52*

− 18.989

 < 0.001

34.64 ± 13.40

18.37 ± 10.38*

20.458

 < 0.001

Group H (N = 61)

74.88 ± 23.92

87.4 ± 17.11*

− 4.706

 < 0.001

63.95 ± 24.94

87.03 ± 16.32*

− 9.709

 < 0.001

32.39 ± 14.84

16.27 ± 11.55*

10.791

 < 0.001

F

2.369

4.550

  

0.582

7.003

  

2.406

8.497

  

P

0.095

0.011

  

0.559

0.001

  

0.092

 < 0.001

  
  1. *Comparison with low dose group, p < 0.05; PIR: platelet inhibition rate.
Back to article page